Main Sequence

Main Sequence is a deep tech venture firm founded in 2017 that invests from seed to Series B in companies built on scientific research. Its About page describes the firm as co-founded by CSIRO, Australia's national science agency, and the firm's brand assets pair its logo with CSIRO's; the page does not describe CSIRO as an owner or shareholder of the manager, so the relationship is best read as a founding and continuing institutional association rather than ownership. The firm organises its investing around six challenge areas it names as: bridge the gap to space, decarbonise the planet, enable the next intelligence leap, feed 10 billion people, reach humanity scale healthcare, and supercharge industrial productivity. Its About page reports Fund 1 at $240 million, Fund 2 at $310 million, Fund 3 at $450 million commencing in 2023, and 51 companies across Funds 1 and 2.

Over $1B (under management, per the firm's own About page, checked 2026; the same page lists Fund 1 at $240M, Fund 2 at $310M and Fund 3 at $450M, which sum to $1B, so the figure tracks cumulative fund capital rather than a dated mark-to-market AUM) AUM 69/100 Power Score™ 2017 Founded
Deep Tech Space Climate Energy Artificial Intelligence Food & Agriculture Healthcare Industrial Technology
View Live Interactive Profile → Visit Main Sequence's Website ↗

Signature Exit

Cylite (acquisition, 2024)

Key Partners & Leadership

Managing Partner
Partner
Partner
Partner
Partner

Firm Timeline

2017
Main Sequence is founded, co-founded by CSIRO, Australia's national science agency, per the firm's About page.
2023
Fund 3 commences at $450 million, per the firm's About page.
2024
The acquisition of portfolio company Cylite is described by the firm as the first material return for its investors.